Cargando…

Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study

BACKGROUND: People who inject drugs (PWID) living with HIV often experience sub-optimal antiretroviral therapy (ART) treatment outcomes, including HIV plasma viral load (PVL) rebound. While previous studies have identified risk factors for PVL rebound among PWID, no study has examined the perspectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Small, Will, Milloy, M. J., McNeil, Ryan, Maher, Lisa, Kerr, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960678/
https://www.ncbi.nlm.nih.gov/pubmed/27462360
http://dx.doi.org/10.1186/s12981-016-0108-9
_version_ 1782444566389981184
author Small, Will
Milloy, M. J.
McNeil, Ryan
Maher, Lisa
Kerr, Thomas
author_facet Small, Will
Milloy, M. J.
McNeil, Ryan
Maher, Lisa
Kerr, Thomas
author_sort Small, Will
collection PubMed
description BACKGROUND: People who inject drugs (PWID) living with HIV often experience sub-optimal antiretroviral therapy (ART) treatment outcomes, including HIV plasma viral load (PVL) rebound. While previous studies have identified risk factors for PVL rebound among PWID, no study has examined the perspectives of PWID who have experienced PVL rebound episodes. We conducted an ethno-epidemiological study to investigate the circumstances surrounding the emergence of rebound episodes among PWID in Vancouver, BC, Canada. METHODS: Comprehensive clinical records linked to a community-based prospective observational cohort of HIV-positive drug users were used to identify PWID who had recently experienced viral rebound. In-depth qualitative interviews with 16 male and 11 female participants explored participant perspectives regarding the emergence of viral rebound. A timeline depicting each participant’s HIV viral load and adherence to ART was used to elicit discussion of circumstances surrounding viral rebound. FINDINGS: Viral rebound episodes were shaped by interplay between various individual, social, and environmental factors that disrupted routines facilitating adherence. Structural-environmental influences resulting in non-adherence included housing transitions, changes in drug use patterns and intense drug scene involvement, and inadequate care for co-morbid health conditions. Social-environmental influences on ART adherence included poor interactions between care providers and patients producing non-adherence, and understandings of HIV treatment that fostered intentional treatment discontinuation. CONCLUSIONS: This study describes key pathways which led to rebound episodes among PWID receiving ART and illustrates how environmental forces may increase vulnerability for non-adherence leading to treatment failure. Our findings have potential to help inform interventions and supports that address social-structural forces that foster non-adherence among PWID.
format Online
Article
Text
id pubmed-4960678
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49606782016-07-27 Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study Small, Will Milloy, M. J. McNeil, Ryan Maher, Lisa Kerr, Thomas AIDS Res Ther Research BACKGROUND: People who inject drugs (PWID) living with HIV often experience sub-optimal antiretroviral therapy (ART) treatment outcomes, including HIV plasma viral load (PVL) rebound. While previous studies have identified risk factors for PVL rebound among PWID, no study has examined the perspectives of PWID who have experienced PVL rebound episodes. We conducted an ethno-epidemiological study to investigate the circumstances surrounding the emergence of rebound episodes among PWID in Vancouver, BC, Canada. METHODS: Comprehensive clinical records linked to a community-based prospective observational cohort of HIV-positive drug users were used to identify PWID who had recently experienced viral rebound. In-depth qualitative interviews with 16 male and 11 female participants explored participant perspectives regarding the emergence of viral rebound. A timeline depicting each participant’s HIV viral load and adherence to ART was used to elicit discussion of circumstances surrounding viral rebound. FINDINGS: Viral rebound episodes were shaped by interplay between various individual, social, and environmental factors that disrupted routines facilitating adherence. Structural-environmental influences resulting in non-adherence included housing transitions, changes in drug use patterns and intense drug scene involvement, and inadequate care for co-morbid health conditions. Social-environmental influences on ART adherence included poor interactions between care providers and patients producing non-adherence, and understandings of HIV treatment that fostered intentional treatment discontinuation. CONCLUSIONS: This study describes key pathways which led to rebound episodes among PWID receiving ART and illustrates how environmental forces may increase vulnerability for non-adherence leading to treatment failure. Our findings have potential to help inform interventions and supports that address social-structural forces that foster non-adherence among PWID. BioMed Central 2016-07-25 /pmc/articles/PMC4960678/ /pubmed/27462360 http://dx.doi.org/10.1186/s12981-016-0108-9 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Small, Will
Milloy, M. J.
McNeil, Ryan
Maher, Lisa
Kerr, Thomas
Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study
title Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study
title_full Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study
title_fullStr Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study
title_full_unstemmed Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study
title_short Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study
title_sort plasma hiv-1 rna viral load rebound among people who inject drugs receiving antiretroviral therapy (art) in a canadian setting: an ethno-epidemiological study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960678/
https://www.ncbi.nlm.nih.gov/pubmed/27462360
http://dx.doi.org/10.1186/s12981-016-0108-9
work_keys_str_mv AT smallwill plasmahiv1rnaviralloadreboundamongpeoplewhoinjectdrugsreceivingantiretroviraltherapyartinacanadiansettinganethnoepidemiologicalstudy
AT milloymj plasmahiv1rnaviralloadreboundamongpeoplewhoinjectdrugsreceivingantiretroviraltherapyartinacanadiansettinganethnoepidemiologicalstudy
AT mcneilryan plasmahiv1rnaviralloadreboundamongpeoplewhoinjectdrugsreceivingantiretroviraltherapyartinacanadiansettinganethnoepidemiologicalstudy
AT maherlisa plasmahiv1rnaviralloadreboundamongpeoplewhoinjectdrugsreceivingantiretroviraltherapyartinacanadiansettinganethnoepidemiologicalstudy
AT kerrthomas plasmahiv1rnaviralloadreboundamongpeoplewhoinjectdrugsreceivingantiretroviraltherapyartinacanadiansettinganethnoepidemiologicalstudy